Contact DMCA Privacy

Robuta

https://pubmed.ncbi.nlm.nih.gov/40055759/
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162...
SAR-SC 200 mg biweekly initiation was associated with a statistically significantly greater decrease in disease activity than TCZ-SC 162 mg biweekly in...
comparative effectivenesssubcutaneoussarilumabmgbiweekly